Eloxx Pharmaceuticals, Inc.
ELOX evidence brief
What we can confirm
- BioSniper Score:
- 6.7 / 10
- Market Cap:
- $62.7M
- Lead Asset:
- exaluren (Phase 2)
What it means
What to watch
Prepared research question
What matters most for ELOX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ELOX
Eloxx Pharmaceuticals, Inc. is a pre-revenue biotech company developing exaluren, a novel small-molecule PTC readthrough drug candidate for nonsense-mutation genetic diseases, currently in Phase 2b clinical trials for Alport syndrome.
Key risk: Single-product dependency
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 3 clinical trials for Eloxx Pharmaceuticals, Inc..
Eloxx Pharmaceuticals, Inc. is a pre-revenue biotech company developing exaluren, a novel small-molecule PTC readthrough drug candidate for nonsense-mutation genetic diseases, currently in Phase 2b clinical trials for Alport syndrome.
- Eloxx has no approved products and relies entirely on its lead candidate exaluren, a small molecule designed to promote PTC readthrough for nonsense-mutation diseases [sec · filed 2026-09-11].
- Cash & equivalents were $62.0M as of 2026-06-30, with net income of -$4.5M and zero debt [sec].
- A Phase 2b trial for exaluren in NMAS patients began in Q3 2026; topline data from the initial 16-week placebo-controlled part is expected by mid-2027 [sec · filed 2026-09-11].
- In August 2025, Eloxx secured $17M in new capital ($15M from Coastlands, $2M from Domicilium) and converted all outstanding indebtedness [sec · filed 2026-09-11].
- The company also has a second candidate, ZKN-013, in preclinical development for other nonsense-mutation diseases [sec_mda · as of 2026-09-11].
What works
- Eloxx has a clear, focused strategy on a validated mechanism (PTC readthrough) for a defined patient population (nonsense-mutation diseases), with exaluren showing potential in Phase 2a [sec · filed 2026-09-11].
- The company recently strengthened its balance sheet by raising $17M and eliminating all debt, providing cash runway to fund the ongoing Phase 2b trial [sec · filed 2026-09-11].
- Eloxx has engaged with the FDA on trial design, suggesting regulatory alignment for its Phase 2b program [sec · filed 2026-06-01].
What to weigh
- Eloxx has no approved products and is entirely dependent on exaluren; failure or delay in its development would materially harm the business [sec · filed 2026-09-11].
- The company has a history of operating with limited resources and reduced headcount, and net losses may fluctuate significantly [sec_mda · as of 2026-08-11].
- Expenses are expected to increase as clinical development advances, and the company may need additional capital to continue as a going concern [sec · filed 2026-06-01].
- Eloxx does not intend to pay dividends for the foreseeable future, retaining all earnings for operations [sec · filed 2026-06-01].
From the filings
Quoted directly from source documents.
Exaluren is the primary product candidate and has no approved products.
“We currently have no products approved for sale. We have invested substantial efforts and financial resources primarily in the research and development of exaluren, which is currently our primary product candidate in clinical development.”
SEC filings · September 11, 2026
Phase 2b trial initiated in Q3 2026 with topline data expected mid-2027.
“we initiated a Phase 2b clinical trial in the third quarter of 2026 for exaluren in NMAS patients and anticipate topline data from the initial 16-week placebo-controlled part of the study by mid-2027”
SEC filings · September 11, 2026
Company raised $17M and converted all debt in August 2025.
“In August 2025, we entered into a securities purchase agreement with Coastlands Capital Partners LP ("Coastlands"), pursuant to which Coastlands invested $15.0 million and Domicilium invested $2.0 million and converted all of our outstanding indebtedness.”
SEC filings · September 11, 2026
Catalyst timeline
- 2026-06-30 · Phase 2b trial start for exaluren in Alport syndrome with nonsense mutations — A randomized, double-blind, placebo-controlled, delayed-start study to evaluate efficacy and safety of exaluren in Alport syndrome patients with nonsense mutations in COL4A3/4/5 genes.
Risks & what to watch (4)›
Key risks
- Single-product dependency — Exaluren is the sole clinical candidate; failure or delay would severely impact the company [sec · filed 2026-09-11].
- No revenue and ongoing losses — Net loss of $4.5M in latest period; no approved products generate revenue [sec].
- Capital needs for continued operations — Expenses will rise with clinical development; additional financing may be required [sec · filed 2026-06-01].
- Clinical trial execution risk — Delays in enrollment or completion could derail timelines and increase costs [sec_mda · as of 2026-08-11].
What to watch
- Topline data from the Phase 2b exaluren trial expected by mid-2027 [sec · filed 2026-09-11].
- Ability to uplist shares to Nasdaq Capital Market and maintain SEC compliance [sec · filed 2026-06-01].
- Progress of ZKN-013 and other preclinical candidates [sec_mda · as of 2026-09-11].
- Cash burn rate and any future capital raises [sec · filed 2026-06-01].
Sources: Catalysts · SEC filings · SEC MD&A · Generated September 30, 2026 · How we verify sources →
Run Eloxx Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Eloxx Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.37 · 0% dilution
Lead: Phase 2
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of May 1, 2026- % of float
- 0.8%
- Days to cover
- 0.7
- Shares short
- 21,485
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ELOX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Eloxx Pharmaceuticals, Inc.?
Eloxx Pharmaceuticals, Inc. is a pre-revenue biotech company developing exaluren, a novel small-molecule PTC readthrough drug candidate for nonsense-mutation genetic diseases, currently in Phase 2b clinical trials for Alport syndrome.
What is Eloxx Pharmaceuticals, Inc.'s lead drug candidate?
Eloxx Pharmaceuticals, Inc.'s most advanced tracked candidate is exaluren (Phase 2) for Alport Syndrome, X-Linked.
Who is the CEO of Eloxx Pharmaceuticals, Inc.?
Mr. Sumit Aggarwal M.B.A. is the chief executive officer of Eloxx Pharmaceuticals, Inc. (ELOX).
Where is Eloxx Pharmaceuticals, Inc. headquartered?
Eloxx Pharmaceuticals, Inc. (ELOX) is headquartered in Arlington, MA, United States.
What therapeutic areas does Eloxx Pharmaceuticals, Inc. focus on?
Eloxx Pharmaceuticals, Inc. develops therapies across Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.